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Abstract
Background: Antipsychotics are recognised as a critical intervention for schizophrenia and bipolar disorder. Guidelines
globally endorse the routine practice of antipsychotic monotherapy, at the minimum effective dose. Even in treatment-
resistant schizophrenia, clozapine use is endorsed before combining antipsychotics.
This aim of this study was to review antipsychotic polytherapy alone, high-dose therapy alone, polytherapy and high-
dose prescribing patterns in adults discharged from an inpatient mental health unit at two time-points, and the
alignment of this prescribing with clinical guideline recommendations. Additionally, associations with polytherapy and
high-dose antipsychotic prescribing, including patient and clinical characteristics, were explored.
Methods: A retrospective clinical audit of 400 adults (200 patients at two different time-points) discharged with at least
one antipsychotic. Preliminary findings and education sessions were provided to physicians between Cohorts.
Outcomes (polytherapy alone, high-dose therapy alone, polytherapy and high-dose therapy) were compared between
study Cohorts using chi-squared and rank-sum tests. Associations between outcomes and covariates were assessed
using multivariable logistic regression.
Results: Most patients (62.5%) were discharged on a single antipsychotic within the recommended dose range. There
was a clear preference for prescribing second generation antipsychotics, and in this respect, prescribing is aligned with
current evidence-based guidelines. However, sub-optimal prescribing practices were identified for both Cohorts in
relation to polytherapy and high-dose antipsychotic rates. Involuntary treatment, frequent hospitalisations and previous
clozapine use significantly increased the risk of all three prescribing outcomes at discharge.
Conclusions: In a significant minority, antipsychotic prescribing did not align with clinical guidelines despite increased
training, indicating that the education program alone was ineffective at positively influencing antipsychotic prescribing
practices. Further consideration should be given when prescribing antipsychotics for involuntary patients, people with
frequent hospitalisations, and those who have previously trialled clozapine.
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Background
Optimal management of serious mental illnesses, such as
schizophrenia, bipolar affective disorder and other psych-
otic disorders, focuses on both symptom and functional re-
covery with a range of pharmacological, psychosocial and
psychological interventions. Antipsychotic medication is
widely recognised as a critical intervention in both acute
and ongoing treatment of schizophrenia [1, 2], and more
recently in bipolar disorder [3, 4].
Clinical practice guidelines globally endorse the routine
practice of monotherapy with antipsychotic medication, at
the minimum effective dose, for people with schizophrenia
or bipolar disorder [1, 2, 4, 5]. Even in treatment-resistant
schizophrenia, i.e. treatment failure with two different
antipsychotic agents, clozapine use is endorsed before
combining antipsychotic therapies [1, 2, 5, 6]. The use of
more than one antipsychotic is only recommended for
short periods when switching treatments [7], or for people
with treatment-resistant schizophrenia who have had only
a partial response to clozapine [1]. Other plausible reasons
include: if a person refuses to take clozapine, or there is a
contraindication or intolerability to clozapine as it is asso-
ciated with a significant side effect profile [8]. Reasons for
clozapine ineffectiveness must be explored before adding
a second antipsychotic, e.g. consumer engagement with
clozapine therapy (i.e. adherence) and other medication
use [1]. In their review of treatment-resistant schizophre-
nia, Dold and Leucht confirmed the continuing uncer-
tainty as to which antipsychotic to recommend if
clozapine is inappropriate [9]. Current Australian guide-
lines outline two choices: i) augmentation with another
antipsychotic or electroconvulsive therapy, or ii) switch to
another agent [2].
In spite of the above recommendations, antipsychotic
polytherapy, or high-dose antipsychotic prescribing, or
both, appears to be common practice [10–12]. Between
1970 and 2009, the globally pooled median antipsychotic
polytherapy rate was 19.6% [13]. The 2010 Australian
National Survey of Psychosis identified that 28% (n = 240)
of participants with schizophrenia were taking two or
more antipsychotics [14]. There are significant concerns
with antipsychotic polytherapy and dosing above thera-
peutic recommendations. These include, but are not lim-
ited to, lack of evidence to support efficacy [15], reduced
medication adherence, drug interactions, increased treat-
ment burden, e.g. financial costs and adverse effects, and
mortality [7, 16].
Variables suggested to be associated with antipsychotic
polytherapy include residual psychotic symptoms [17], be-
ing treated involuntarily [18], psychiatrists prescribing be-
liefs and clinical experience [19], and hospitalisation or
longer hospital stays, which may be influenced by duration
of illness [20–23]. One of the strongest predictors of high
antipsychotic doses is the prescribing of more than one
antipsychotic concurrently [23–26]. Overall, there is con-
flicting evidence for associations between patient charac-
teristics and either antipsychotic polytherapy or high-
dosing, such as age [18, 23, 27, 28] and ethnicity [27–31].
For instance males have been reported to be at greater
risk, or have higher rates of these outcomes [18, 23, 27,
29], yet this was not demonstrated in New Zealand [28].
Audit and feedback (clinical audit) is an intervention
commonly undertaken by organisations to monitor and
improve the quality of health care. A clinical audit ‘com-
pares actual practice with an optimal standard of prac-
tice’ [32]; this is integral for evaluating and improving
practices and ultimately, patient safety and care. It is a
cycle that follows a systematic process of establishing
best practice, evaluating care against explicit criteria,
implementing steps to improve care, and monitoring for
continual improvement [33, 34]. The aim of this paper is
to review polytherapy and high-dose antipsychotic pre-
scribing patterns in adults discharged from an inpatient
mental health unit at two time-points, and the alignment
of this prescribing with clinical guideline recommenda-
tions. Additionally, this paper explores associations with
polytherapy and high-dose antipsychotic prescribing, in-
cluding patient and clinical characteristics.
Methods
This study was a single-centre, retrospective clinical audit
of 400 adults discharged with a prescription for at least
one antipsychotic medication from a Queensland-based
metropolitan public hospital. The hospital is the largest of
three adult psychiatric hospitals in the region covering a
catchment area of approximately one million people. The
hospital functions as a major teaching hospital, and has 67
adult psychiatric inpatient beds, which treats both volun-
tary and involuntary patients admitted under the relevant
legislation [35]. The catchment area also encompasses a
large culturally and linguistically diverse population.
Information was obtained for 200 patients at two dif-
ferent time-points: patients discharged on or before the
31st January 2014 (Cohort 1), and on or before the 31st
January 2015 (Cohort 2). This sample size was deemed
large enough to provide adequate statistical power and
an accurate reflection of hospital prescribing practices.
The time points were chosen to allow for education
interventions to be provided at the start of a new trainee
year, with trainees beginning their first term of 2014 at
the start of February. Rotations for training psychiatry
registrars through the Royal Australian and New Zea-
land College of Psychiatrists (RANZCP) are generally
6 months’ duration for full-time trainees [36]. It was an-
ticipated that education interventions would occur over
a period of 5–10 months. It was acknowledged that the
majority of education interventions were targeted to-
wards training psychiatrists. This was done in a
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purposeful manner with training psychiatrists noted to
generally have greater contact with patients and more
frequent review of psychotropic medication prescription
(under the guidance of supervising psychiatrists).
At the time of study (between Cohorts), the hospital ran
a regular education program on Monday afternoons, for
mental health medical staff (psychiatrists and training psy-
chiatrists). Antipsychotic education was included during
these sessions in a number of ways such as: a one-hour
presentation by a pharmacy student highlighting the issues
from a preliminary analysis of Cohort 1 findings; a one-
hour presentation that was video-conferenced to three hos-
pital sites across the district presented by a training psych-
iatrist which specifically addressed high-dose antipsychotic
prescribing and antipsychotic polypharmacy. In addition,
four pharmacology sessions were provided to psychiatric
trainees discussing the rational and appropriate use of psy-
chotropic medications. These teaching sessions were con-
ducted from February to October 2014. Pharmacology
teaching to training psychiatrists was positively received,
whilst education sessions on antipsychotic polypharmacy
and high-dose antipsychotic use presented to consultant
psychiatrists and training psychiatrists were met with a var-
iety of responses, including defence of antipsychotic poly-
pharmacy despite a lack of supporting evidence. Hospital
mental health pharmacists were also invited to attend these
education sessions, and a dedicated presentation of findings
from Cohort 1 was presented to the greater hospital phar-
macy group.
Ethical approval was obtained from both a University
(HSV/04/15/HREC) and District Health Board (EC00167)
Ethics Committee. The records for the most recent 200
adult patients discharged prior to each of the two time-
points with at least one antipsychotic prescribed, irrespect-
ive of diagnosis, were obtained (Cohort 1: January 31, 2014
to November 27, 2013; Cohort 2: January 31, 2015 to De-
cember 2, 2014). Patients were excluded if they were trans-
ferred to another ward, unit or hospital, became ‘absent
without permission’ during their inpatient admission, or
died during the admission (82 and 73 patients were ex-
cluded from each cohort respectively). For patients with
multiple hospital discharges, only the most recent discharge
in each Cohort was included (i.e. the one closest to the 31st
January for each time-point). Nineteen patients were com-
mon to both cohorts. There were no significant changes
made to the service delivery model between the two review
periods.
Three electronic databases were used, by two psych-
iatry registrars (Cohort 1) and two Master of Pharmacy
students (Cohort 2) to obtain study data (Fig. 1). Infor-
mation was de-identified with a unique identifier used
for study data entry in Microsoft Excel®. A briefing ses-
sion and procedure guide ensured that all researchers
followed a standardised data collection process. A post-
data entry meeting was held to combine data from the
two Cohorts, and to identify and resolve any discrepan-
cies. The following definitions were used for data collec-
tion and analysis by the researchers:
 Antipsychotic polytherapy: prescribing of two or
more different antipsychotic agents simultaneously,
or prescribing two or more different formulations of
the same antipsychotic medication, including ‘when
required;’
 High-dose prescribing (total antipsychotic equivalent
dose): The sum of the total daily dose (TDD) of
each antipsychotic used by a patient within 24 h
divided by the recommended maximum daily dose
[37, 38]. A total equivalent dose greater than one
was classified as a high-dose;
 Ethnicity: country of birth; and,
 Involuntary treatment: included both an Involuntary
Treatment Order (ITO) and a Forensic Order (FO).
An ITO is endorsed by a psychiatrist and authorises
a person to receive mental health treatment without
consent. Alternatively, an FO is endorsed by the
legal system [35].
Analysis
Data was imported into Stata 14.1 for cleaning and ana-
lysis. Results were presented as frequencies (n) and pro-
portions (%) for categorical data, or median and 25th/75th
percentiles for continuous non-symmetrical data. Baseline
characteristics were compared between cohorts using chi-
HBCIS: Hospital Based Corporate Information System; CIMHA: Consumer Integrated Mental Health Application; eLMS: Enterprise 
Liaison Medication System
Patient Cohort 
Collection (HBCIS)
• Name
• Record number
• Admission date
• Discharge date
Patient 
Demographics 
(CIMHA)
• Gender
• Age
• Ethnicity
Clinical Data 
(CIMHA)
• Number of previous  
mental health 
admissions
• Diagnosis
• ECG/metabolic 
monitoring
Discharge  Summary 
(CIMHA)
• Patient consent
• Mental Health Act 
status
• Follow up plans
• Clozapine trial
• Electroconvulsive 
treatment
Discharge 
Medication Record 
(eLMS)
• Antipsychotic name
• Form
• Dose
• Other medication
• Adverse drug 
reactions
Fig. 1 Data collection process
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squared and rank-sum tests. Associations between therapy
received (polytherapy alone, high-dose therapy alone,
poly- and high-dose therapies) and cohort and other co-
variates were assessed with odds ratios, which were calcu-
lated using multivariable logistic regression. Correlations
between covariates were checked using linear regression
or by calculating pairwise correlation coefficients (all abso-
lute values r < 0.40). Three separate multivariable models
(dependent variable: therapy received) were built using co-
variates presented in Table 4 including cohort. The
models were derived through manual backwards step-wise
removal of covariates at p ≥ 0.05 level. Statistical signifi-
cance was declared at p < 0.05. Only significant odds ra-
tios were presented. Missing values were not imputed. No
adjustment was made for multiple comparisons.
Results
Overall, the majority of discharged patients in both
Cohorts were male, with a similar median age (38
years, Cohort 1; 35 years Cohort 2; Table 1). Over
three-quarters of Cohort 1 (n = 152; 76.0%) and two-
thirds of Cohort 2 (n = 137; 68.0%) participants were
Australian born. Similar proportions were identified
between the two Cohorts with respect to primary
diagnosis; the most prominent condition overall in
the study population was schizophrenia (n = 148;
37.0%). The only significant difference identified be-
tween Cohorts was the higher rate of comorbid sub-
stance use recorded for Cohort 1 (p = 0.001).
Prescribing practices across the two Cohorts were simi-
lar in terms of the antipsychotic medication used (Table
2). Second generation antipsychotics (SGA) were the most
commonly prescribed antipsychotics, in particular risperi-
done was the most commonly prescribed agent (oral (PO)
and long-acting injection (LAI), n = 125), followed by
olanzapine (PO and LAI, n = 123), quetiapine (PO only,
n = 85) and paliperidone (PO and LAI, n = 64).
Table 3 shows that the majority of patients (n = 250/
400; 62.5%) were discharged on a single antipsychotic
medication with a dose within the therapeutic recom-
mendations, i.e. below the maximum recommended
dose (n = 132/200, 66.0% Cohort 1; n = 118/200, 59.0%
Cohort 2). Overall antipsychotic polytherapy as a pre-
scribing outcome at discharge (either alone or with
Table 1 Participant characteristics by Cohorts (n = 400)
Cohort 1
n = 200
Cohort 2
n = 200
Total
n = 400
p-value
Group size 200 (50%) 200 (50%) 400 (100%)
Gender (male) 117 (58%) 119 (60%) 236 (59%) 0.839
Age (years)a 38 (28–48) 35 (28–44) 36 (28–46) 0.059b
Ethnicity
- Australian 152 (76%) 137 (68%) 289 (72%) 0.056
- Asian 20 (10%) 14 (7%) 34 (8%)
- Pacific Islander 13 (6%) 23 (12%) 36 (9%)
- Other 15 (8%) 26 (13%) 41 (10%)
Admissions (last 12 months)
- One or two 157 (78%) 165 (82%) 322 (80%) 0.582
- Three or four 27 (14%) 21 (10%) 48 (12%)
- Five or more 16 (8%) 14 (7%) 30 (8%)
Hospital duration (days)a 8 (4–17) 10 (5–22) 9 (5–19) 0.317c
Primary diagnosis
- Schizophrenia 72 (36%) 76 (38%) 148 (37%) 0.946
- Bipolar disorder 27 (14%) 26 (13%) 53 (13%)
- Other psychotic disorder 30 (15%) 32 (16%) 62 (16%)
- Other 71 (36%) 66 (33%) 137 (34%)
Comorbid substance use disorder 77 (38%) 46 (23%) 123 (31%) 0.001
Involuntary treatment 77 (38%) 84 (42%) 161 (40%) 0.475
Previous clozapine trial 23 (12%) 20 (10%) 43 (11%) 0.628
n (%) shown unless otherwise noted
amedian and inter-quartile range (25th and 75th percentiles) shown; p-values calculated with chi-squared test unless otherwise noted
bWilcoxon rank-sum test
cmedian test
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high-dose antipsychotic therapy) was found in just less
than a third (n = 130/400; 32.5%) of the study popula-
tion (n = 56, 28.0% Cohort 1; n = 74, 37.0% Cohort 2).
Overall high-dose antipsychotic therapy as a prescribing
outcome at discharge (either alone or with antipsychotic
polytherapy) was found in 20.5% (n = 82/400) of the
study population (n = 36/200, 18.0% Cohort 1; n = 46/
200, 23.0% Cohort 2). A total of 62 patients (15.5%) were
prescribed both antipsychotic polytherapy and high-dose
therapy at discharge (n = 24/200, 12.0% Cohort 1;
n = 38/200, 19.0% Cohort 2).
Associations with polytherapy and high-dose
antipsychotic prescribing
Associations between three antipsychotic prescribing out-
comes at discharge: (i) polytherapy only; (ii) high-dose ther-
apy only; and (iii) polytherapy and high-dose therapy
together were investigated in a regression model with the
following variables: Cohort, participant demographics, hos-
pital admissions in the last 12 months, primary diagnosis,
comorbid substance use disorder, involuntary treatment
status and previous clozapine trial (Table 4).
There was a difference between Cohorts with respect
to two outcomes: (i) polytherapy alone, and (iii) poly-
therapy and high-dose together; patients in Cohort 2
were 1.8 times more likely to be discharged on polyther-
apy alone and more than twice as likely to be discharged
on polytherapy and high-dose therapy together. No sig-
nificant associations were identified between the three
outcomes and patients’ age, gender, ethnicity, and having
a comorbid substance use disorder.
Those patients who had five or more admissions in
the previous 12 months were significantly more likely to
be discharged on (i) antipsychotic poytherapy alone and
(iii) polytherapy and high-dose therapy together; the risk
of polytherapy alone at discharge was 7.5 times more
likely and polytherapy and high-dose therapy together
was 5.3 times more likely compared to those patients ad-
mitted less frequently.
Compared to patients with schizophrenia, those with
all other diagnoses were significantly less likely to be
prescribed polytherapy alone. The likelihood of anti-
psychotic polytherapy plus high-dose therapy was similar
between patients diagnosed with schizophrenia and
those with other psychotic disorders, but was signifi-
cantly lower for those with bipolar and other disorders.
Involuntary treatment and previous clozapine use sig-
nificantly increased the risk of all three prescribing out-
comes at discharge (Table 4).
Discussion
Overall, this study found that the majority of patients
(62.5%) were discharged on a single antipsychotic within
the recommended dose range. There was a clear prefer-
ence for prescribing SGAs, which are recommended first-
line agents for schizophrenia and schizoaffective disorder
by the RANZCP [2]. In this respect, prescribing is aligned
with current evidence-based guidelines. However, sub-
optimal prescribing practices were identified for both
Table 2 Antipsychotics prescribed on discharge
Class Route First AP Second AP Third AP
SGA C1 C2 C1 C2 C1 C2
Amisulpride PO 2 5 2 5
Aripiprazole LAI 1
PO 4 10 2 1
Asenapine PO 2 1
Clozapine PO 17 13 2
Olanzapine LAI 4 1
PO 45 45 12 16
Paliperidone LAI 18 34 3 7
PO 1 1
Quetiapine PO 39 31 6 7 2
Rispiridone LAI 13 6 5 4
PO 34 38 11 14
Ziprasidone PO 3 1
Subtotal IM 35 41 8 12
PO 146 144 34 46 2
FGA C1 C2 C1 C2 C1 C2
Chlorpromazine PO 2 2 1 3 2
Flupenthixol LAI 2 2 3 3
Fluphenazine LAI 2
Haloperidol LAI 2 1
PO 2 1 1 1
Zuclopenthixol LAI 11 10 5 6
PO 2 1
Subtotal IM 15 12 9 11
PO 4 3 4 5 2
AP Total IM 50 53 17 23
PO 150 147 38 51 4
TOTAL 200 200 55 74 4
SGA Second generation antipsychotic, FGA First generation antipsychotic, PO
oral; LAI Long-acting injection, AP Antipsychotic, C1 Cohort 1, C2 Cohort 2
Table 3 Therapy received by cohort
Therapy received Frequency
Polytherapy High dose Cohort 1
n = 200
Cohort 2
n = 200
Total
N = 400
No no 132 118 250
Yes no 32 36 68
No yes 12 8 20
Yes yes 24 38 62
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Cohorts in relation to polytherapy and high-dose anti-
psychotic rates. Subsequently, a number of patients were
at risk of adverse consequences as a result of their dis-
charge treatment. This was despite increased clinician
education prior to the second time-point (Cohort 2),
reflecting the need for a review of the training provided at
a local level and in wider medical education. Our audit
results provide further evidence that gender, age and eth-
nicity are not associated with polytherapy or high dose
[26, 28], although the ethnic minority groups made up
only about 30% of each Cohort. Patients with a primary
diagnosis of schizophrenia were identified to be at signifi-
cantly greater risk of polytherapy alone or polytherapy and
high dose antipsychotic use. Lastly, polytherapy alone,
high antipsychotic dose alone, and polytherapy/high-dose
therapy combined were significantly associated with the
following three consumer variables: five or more previous
hospital admissions within the last 12 months, involuntary
treatment and previous clozapine use.
These results should be considered with respect to
other recent research in this area. A similar audit was
conducted with 272 inpatients in Portugal in 2012 [39].
Compared to our study, Campose-Mendes et al. identi-
fied a higher proportion of patients on polytherapy, as
well as those on high dose therapy [39]; this may be ex-
pected with an audit undertaken in 12 psychiatric units
compared to our one. Involuntary treatment and prior
psychiatric admission was found to be associated with
high dose in both studies [39]. Our study did not explore
associations depending on the formulation of the anti-
psychotic or employment status.
The frequency of antipsychotic polytherapy alone was
similar between the two Cohorts, and it was encouraging to
see that the majority of patients were being treated with
one antipsychotic. The total rates of any antipsychotic
polytherapy in this study were lower than those reported in
a small Australian audit of hospital inpatients with
schizophrenia [40]; Malhi et al. did not investigate associ-
ated high-dose antipsychotic prescribing.
While our relatively low rate of antipsychotic polyther-
apy alone could be viewed positively, this needs to be
considered in association with high dosing or whether
clozapine has been trialled. A similar proportion of pa-
tients were discharged with polytherapy and high-dose
therapy, particularly those patients in Cohort 2. An in-
vestigation into what drives this outcome is needed in
this clinical setting; was a second (or third) antipsychotic
agent added after an increased dose or vice versa? As
polytherapy and high antipsychotic dosing escalates the
risk of adverse effects, which can lead to rehospitalisa-
tion, the consequences of, and lack of supportive evi-
dence for such a combination, must be reiterated to
clinicians. This audit emphasises the need to develop
further strategies to reduce these rates in this particular
hospital. However, it is noted that the audit specific-
ally gathered clinical information from discharge sum-
maries and pharmacy software at a cross-sectional
time-point. With a high acuity of psychiatric illness in
Table 4 Multivariable logistic regressions (associations between therapy received and cohort/other covariates)
Adjusted odds ratio (95% CI) of therapy received
Therapy received Polytherapy High dose Polytherapy and high dose
Model size n = 400 n = 400 n = 312
Cohort (base: 1st) 1.81 (1.08–3.02)* - 2.14 (1.10–4.17)*
Gender (base: male) - - -
Age (year) - - -
Ethnicity (base: Australian) - - -
Adm. in last 12 m (base: one or two):
- three or four 1.77 (0.87–3.60) - 2.28 (0.97–5.35)
- five or more 7.52 (2.92–19.4)* - 5.30 (1.57–17.8)*
Hospital stay (day) ^ ^ ^
Primary diagn. (base: schizophrenia):
- bipolar disorder 0.19 (0.08–0.47)* - 0.26 (0.08–0.80)*
- other psychotic disorder 0.33 (0.14–0.75)* - 0.33 (0.11–1.00)
- other 0.40 (0.21–0.76)* - 0.40 (0.17–0.91)*
Comorbid substance use disorder - - -
Involuntary treatment 3.95 (2.31–6.77)* 2.22 (1.34–3.66)* 3.18 (1.61–6.29)*
Previous clozapine trial 5.80 (2.43–13.8)* 2.19 (1.10–4.38)* 5.58 (2.04–15.3)*
CI confidence interval, * p < 0.05; hyphen = excluded from multivariable model at p ≥ 0.50; ^ = excluded due to multicorreality; m months, diagn. diagnosis,
adm. admissions
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the inpatient psychiatric unit, and increasing referrals,
there are increased pressures for access to inpatient
psychiatric beds and reduced length of stay. It is
therefore plausible that patients may be discharged on
antipsychotic polypharmacy with a plan to reduce and
cease this following discharge.
Clozapine use is the most effective medication for
treatment-resistant schizophrenia [41], and would cir-
cumvent the need for antipsychotic polytherapy for
many patients. Only 11% (n = 43) of the total number of
patients in this audit were trialled on clozapine. This low
number may have been influenced by psychiatrist pre-
scribing experiences and beliefs, underscoring the pre-
disposition for clinicians to delay prescribing clozapine
for patients with treatment-resistant schizophrenia [28].
This tendency is believed to be influenced by a range of
factors, including but not limited to, clozapine’s serious
adverse effect profile [42], and the perception that con-
sumers are less satisfied with this treatment choice [43].
While this practice appears to be improving internation-
ally [44] and in Australia [41], further investigation is
needed as to the reasons for low clozapine prescribing
rates in this particular hospital setting. What is known is
that the increased education between Cohorts did not
specifically focus on the indications and utility of cloza-
pine. Furthermore, by sourcing clinical data from dis-
charge summaries which are supposedly designed to be
the primary clinical communication tool on discharge
and transfer of care, these may not always be compre-
hensively authored and may therefore omit information
in regards to prior clozapine trials. An underestimation
of the rate of patients previously trialled on clozapine is
therefore possible. It should be noted that for those pa-
tients with a previous clozapine trial, there was a greater
likelihood of being prescribed antipsychotic polytherapy
or polytherapy and/or high-dose. The reasons behind
treatment failure with clozapine were unable to be ex-
plored in this study, but underscore the difficulty in
treating patients with treatment-resistant schizophrenia
especially when clozapine treatment has been stopped.
Patients diagnosed with schizophrenia in our study were
also more likely to be prescribed antipsychotic polytherapy
alone or with high-dose compared to those with bipolar
disorder or other mental illness. The association with poly-
therapy alone is supported by a US based audit of outpa-
tients visiting office-based psychiatrists [11]; other inpatient
studies did not explore such associations [45], or focused
solely on patients with a diagnosis of schizophrenia or re-
lated disorder [22, 24, 25]. Antipsychotics are often not
first-line treatment for other mental illnesses, such as bipo-
lar disorder. Thus, the significant relationship found be-
tween diagnosis and antipsychotic polytherapy was to some
extent expected given that the majority of patients in both
Cohorts had a primary diagnosis of schizophrenia.
Involuntary treatment was found to be significantly as-
sociated with antipsychotic polytherapy, with increased
rates or similar associations seen in other countries [18,
46]. These vulnerable patients were also more likely to
be prescribed high dose, or both polytherapy and high
dose antipsychotics. Similarly, other research has con-
firmed that compulsory detention/involuntary patients
are at a greater risk of being prescribed high anti-
psychotic doses [18, 24, 47, 48].
People hospitalised more than five times in the previ-
ous year were significantly more likely to be prescribed
more than one antipsychotic. These consumers would
have been clinically unstable; multiple antipsychotics are
likely to have been prescribed as an attempt to stabilise
the patient. This result underscores the need for clini-
cians to take particular care and attention towards both
of the above vulnerable patient groups, and the reasons
for such high hospitalisation rates, e.g. side effects, non-
adherence, ineffective treatment, etc. must be investi-
gated. In particular, the role of shared-decision making
can be particularly important in this context; a qualita-
tive study exploring this concept with mental health
pharmacists identified the view that involving patients
with serious mental illnesses in treatment decisions
would improve adherence and clinical outcomes [49]. It
is not known to what degree, shared-decision making
was utilised in this hospital setting for audit participants
as this data was not specifically captured. It is however
noted that person-centred care is a core value of the ser-
vice. Future audits in this area should consider the inclu-
sion of shared-decision making as an additional variable.
Fewer variables were found to be associated with any
high antipsychotic dosing compared to antipsychotic
polytherapy. Of concern, however, is that overall 20% of
patients were prescribed a high antipsychotic dose, pla-
cing these patients at a higher risk of adverse effects.
While there are variable definitions of ‘high dose,’ the
prevalence of solely high-dose prescribing in this audit
was higher than that of discharged patients from a UK
psychiatric ward (6.8%) [50] and Hong Kong inpatients
(9.2%) [47].
An escalation protocol for identification of prescribing
practices considered potentially dangerous and the need
for out-of-study follow-up by an independent senior
psychiatrist was included in our research design for eth-
ics approval. In the event, no patients were identified to
require use of this escalation pathway.
Future research and practice recommendations
The observed sub-optimal antipsychotic prescribing
practices at discharge from this hospital demonstrates a
need for future improvement. Prescribers (training
psychiatry registrars and consultant psychiatrists) need
to explain the justification for treatment choices in key
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handover documentation such as discharge summaries.
Despite the RANZCP Clinical Practice Guidelines for
the Management of Schizophrenia being eight to 10 years
old over the time-periods that the audit was conducted,
there were deviations from recommended practice. Add-
itionally, there remains a recommendation in the litera-
ture for antipsychotic monotherapy and the use of
clozapine.
The preliminary results of the audit have influenced
the service to develop a dedicated committee to explore
and develop treatment pathways for psychosis. Through
this committee, draft guidelines on the treatment of
psychosis which further address aspects of care dis-
cussed in the audit such as antipsychotic polypharmacy,
high dose antipsychotic prescription, the use of cloza-
pine, and further augmentation strategies in treatment-
resistant psychosis have been developed. These locally
specific guidelines are based on current evidence and in-
dicate a requirement to obtain consultant psychiatrist
approval for high dose antipsychotic and antipsychotic
polypharmacy prescription, and emphasise the need to
clearly document and justify individual patient treatment
decisions. The draft version of the treatment pathway
for psychosis guidelines has been distributed to all train-
ing psychiatry registrars and consultant psychiatrists
across the service for comment. Following finalisation of
these guidelines, implementation, and a period of prac-
tice, it would be useful to analyse a third Cohort of pa-
tients to determine if there is a subsequent beneficial
change to prescribing practices.
Inclusion and review of all psychotropic medications
may provide a better understanding of clinical decision-
making and the extent of psychotropic polypharmacy as
a whole and thus total medication burden experienced
by patients. Furthermore, many cases of polytherapy in
our study involved combinations of oral and LAI
antipsychotics; rationale for this combination regimen
were not explored. Whilst this practice is not uncommon
[51, 52], there is little evidence to support this practice, es-
pecially if the LAI antipsychotic was introduced to man-
age adherence problems with an oral medication. This is
worthy of further exploration to identify patients at risk of
poor treatment outcomes [51].
An aspect of psychiatric care not explored in the audit
was the utilisation of pharmacists with specialist mental
health expertise. This audit and the pool of literature ref-
erenced highlight the considerable variability in regards
to psychiatric treatments, and the potential for negative
impacts on morbidity and mortality. A future area of re-
search may seek to compare prescribing practices in psy-
chiatric units with dedicated mental health pharmacists
and those without. If significant differences are noted,
this may inform service delivery, policy creation and
workforce reforms.
Strengths and limitations
Study strengths include the standardised data collection
process and large sample size. With procedural guidelines
followed by all researchers, and regular debriefs, this en-
sured that data was collected and recorded accurately and
consistently. This audit contributes to the literature by
providing a better understanding of antipsychotic poly-
therapy and high-dose prescribing, their relationship and
risk factors associated with this practice. Furthermore, this
study was more inclusive by involving patients with condi-
tions beyond schizophrenia. Finally, a key strength of this
study was the exploration of variables associated with
polytherapy and high dose prescribing; many published
studies have focused on one or the other, not both.
However, the audit results should be interpreted
within its limitations. Firstly, as a retrospective study,
the quality of the data was dependent on the accuracy
and completeness of clinical notes. In this particular
hospital setting, clinical notes varied in terms of the
quantity and quality of documented information, and
there was no reliable recording of adverse effects specific
to antipsychotic use. It would have been useful to con-
sider the justification for prescribing long-term polyther-
apy; this information was not consistently recorded by
clinicians. Unlike the work by Kadra et al. [53], the def-
inition of antipsychotic polytherapy used did not include
a time-frame; it may be that some patients were on two
antipsychotics temporarily due to cross-titration, or were
using an oral antipsychotic for short term use whilst
commencing a long acting formulation. This information
could not be identified from patient records alone in this
audit; hence there is a possibility that the rates of poly-
therapy are over-estimated for both Cohorts [51]. With
regards to additional psychotropic prescribing informa-
tion, limited data regarding antidepressants, mood stabi-
lisers and benzodiazepine medications was collected,
however, it was beyond the scope of the study to widen
the focus primarily because of the limited timeframes of
postgraduate student research. Lastly, this audit was sit-
uated in one clinical setting in Australia, limiting the
generalisability to other healthcare settings beyond this
context.
Conclusion
In a significant minority antipsychotic prescribing prac-
tices did not align with clinical guidelines, despite in-
creased education for prescribers in-between Cohorts.
This indicates that the education program alone and well
established clinical practice guidelines (RANZCP) were in-
effective at positively influencing antipsychotic prescribing
practices. The subsequent approach to local guideline de-
velopment is based on the premise of the importance of
prescriber engagement in bringing about practice change.
Overall, it appears that further consideration should be
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given when prescribing antipsychotics for involuntary pa-
tients, people with frequent hospitalisations, and those
who have previously trialled clozapine. The study findings
also highlight the considerable variability in psychiatric
prescribing practices, and the need for further research in-
cluding additional audits and evaluation of the effective-
ness of formal education programs and treatment
guidelines.
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